GLOBAL EPIGENOMICS MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL EPIGENOMICS MARKET FORECAST 2018-2026

GLOBAL EPIGENOMICS MARKET FORECAST 2018-2026

 The global epigenomic market is estimated to grow with approx.18.25% CAGR during the year 2018-2026. Epigenomics can be defined as the study of the whole set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The global epigenomic market is primarily driven by the following factors: Increase in the prevalence of cancer and other chronic diseases

GLOBAL EPIGENOMICS MARKET FORECAST 2018-2026

Global Epigenomics Market by Product (Reagents, Kits, Instruments, Enzymes, Services) by Technology (Dna Methylation, Histone Methylation & Acetylation, Microrna Modification) by Application (Oncology, Non-oncology) by Application Area (Diagnosis, Drug Discovery, Therapy Optimization, Prognosis) by Segment (Epigenetic Diagnosis(Cancer, Neuro, Inflammatory & Autoimmune Disease, R&d, Personalized Medicine, Neurological Disorders, Cvd, Others), Epigenetic Therapies(Biomarkers, Noncoding Rnas, Mirnas, Chromatin Remodeling)) by Geography.

Request free sample

The global epigenomic market is estimated to grow with approx.18.25% CAGR during the year 2018-2026. Epigenomics can be defined as the study of the whole set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The global epigenomic market is primarily driven by the following factors:

  • Increase in the prevalence of cancer and other chronic diseases
  • Increase in the ageing population
  • Decrease in the sequencing costs and time
  • Growth in funding for research & development
  • Need for better cancer therapies
  • Growth in personalized medicine
  • Increasing importance of epigenetic technology

Epigenomics Market

To know more about this report, request a free sample copy.

The important driver increasing growth in the global epigenomic market is an increase in the prevalence of cancer and other chronic diseases. Cancer and other chronic diseases have common risk factors such as ageing and unhealthy lifestyles (for instance: smoking, unhealthy diet, physical inactivity, obesity, and alcohol misuse).

The epigenetic diagnosis segment is a prominent segment of the global epigenomic market. Factors such as growing emphasis among researchers for developing efficient epigenetic diagnosis techniques and growing emphasis among government on the development of efficient healthcare system for all categories of the society are likely to fuel the demand for epigenetic diagnosis over the forecasted period. DNA methylation is the most extensively used technology in epigenomics. Rising demand for DNA methylation due to its application in a broad range of samples, including humans, animals and rodents, is expected to boost the demand over the forecast period.

Inefficiency in identification and validation of biomarker, the presence of complex regulatory framework and lack of reimbursement provision in insurance for epigenomic are the restraints faced by the global epigenomic market.

The Global Epigenomic Market segments include:

  • Market by product
    • Reagents
    • Kits
    • Instruments
    • Enzymes
    • Services
  • Market by technology
    • DNA methylation
    • Histone methylation & acetylation
    • MicroRNA modification
  • Market by application
    • Oncology
      • DNA methyltransferase inhibitors
      • Histone deacetylase inhibitors
    • Non-oncology
  • Market by application area
    • Diagnosis
    • Drug discovery
    • Therapy optimization
    • Prognosis
  • Market by segment
    • Epigenetic diagnosis
      • Cancer
      • Neuro
        • Mental retardation
        • Alzheimer’s disease
        • Depression
        • Other
      • Cardiovascular
        • Vascular disease
        • Heart failure
        • Others
      • Inflammatory & autoimmune disease
        • Rheumatoid arthritis
        • Diabetes
        • Lupus
        • Multiple sclerosis
        • Inflammatory bowel diseases
      • R&D
        • DNA methylation in cancer detection
        • Identification of epigenetic biomarkers for diagnosis and prediction
        • Mechanisms of epigenetic gene silencing
      • Personalized medicine
        • Cancer treatment
          • Lung cancer
          • Solid cancers
          • Gastric cancer
          • Haematological cancers
          • Others
        • Neurological disorders
          • Mental retardation
          • Huntington’s disease
          • Parkinson’s disease
          • Alzheimer’s disease
          • Depression
        • CVD
        • Others
          • Rheumatoid arthritis
          • Diabetes
          • Myelodysplastic syndromes
          • Multiple sclerosis
          • Obesity
          • Inflammatory bowel diseases
          • Lupus
          • Other
        • Epigenetic therapies
        • Biomarkers
          • DNA methylation for cancer detection
          • Histonic modification as a biomarker in cancer detection
            • Histone methylation
            • Histone acetylation
          • Noncoding RNAs
          • MiRNAs
          • Chromatin remodelling

The report scope also covers region-specific trends in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Also, the study strategically identifies and profiles key market players and analyzes their core competencies in each application of the market. and tracks and analyzes the recent market developments and competitive strategies in the global epigenomic market such as partnerships, agreements, collaborations, mergers and acquisitions, new product developments and expansions.

Geographically, the global epigenomic market has been segmented on the basis of four major regions into:

North America market dominates the global epigenomic market in terms of revenue. The market is experiencing an increase in R&D funding due to its promising future perspectives. Also, there is a rise in the number of collaborations between the large pharmaceutical companies to get into innovation and produce technologically advanced and effective products and service. The overall increase in demand for epigenomic drugs and diagnostic techniques is due to an increase in the occurrences of cancer, neuro diseases and cardiovascular diseases. Prominent drivers of the market are the presence of government funding for ongoing research activities on epigenetics, improved healthcare facilities, constantly increasing geriatric population, advanced technological facilities, diligent research, successful initiatives, and accurate diagnostic procedures. On the other hand, the Asia-Pacific epigenomic market is anticipated to grow rapidly, due to the high incidence of cancer, large prevalence of target diseases, the rise in healthcare expenditure, the rise in investments and funds, and various emerging applications.

The major market players in the global epigenomics market are:

  • Abbott Laboratories
  • Affymetrix
  • Agilent Technologies
  • Astellas Pharmaceuticals
  • Bayer Ag
  • Others

Company Profiles covers analysis of important players

These companies are using organic and inorganic strategies for growth. For instance, on 06 April 2018, Roche completed the acquisition of Flatiron Health. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research. Also on January 19, 2017, Rubicon Genomics merged with Takara Bio Group. This merger will increase the accessibility of the company’s products and services on the global market and facilitate the development of innovative new solutions for the customers.

Key Findings of the global epigenomics market:

  • North America leads the market by capturing the largest revenue share
  • Asia Pacific is anticipated to be the most dynamic regional market.
  • Reagents form a major part of the epigenomic market by product
  • Epigenetics diagnosis is a major part of the epigenomic market, and personalized medicines are showing a dynamic growth
  • Oncology is the primary application while non-oncology is showing a better growth
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
    • NORTH AMERICA LEADS THE MARKET BY CAPTURING THE LARGEST REVENUE SHARE
    • ASIA PACIFIC IS ANTICIPATED TO BE THE MOST DYNAMIC REGIONAL MARKET
    • REAGENTS FORM A MAJOR PART OF EPIGENOMIC MARKET BY PRODUCT
    • EPIGENETICS DIAGNOSIS IS A MAJOR PART OF EPIGENOMIC MARKET, AND PERSONALIZED MEDICINES IS SHOWING A DYNAMIC GROWTH
    • ONCOLOGY IS THE PRIMARY APPLICATION WHILE NON-ONCOLOGY SHOWING A BETTER GROWTH
  1. MARKET DYNAMICS
    • MARKET DEFINITION & SCOPE
    • MARKET DRIVERS
      • ADVANCEMENT IN THE PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
      • RISE IN THE AGEING POPULATION
      • DECLINE IN THE SEQUENCING COSTS AND TIME
      • ESCALATION IN FUNDING FOR RESEARCH & DEVELOPMENT
      • NEED FOR BETTER CANCER THERAPIES
      • GROWTH IN PERSONALIZED MEDICINE
      • INCREASING IMPORTANCE OF EPIGENETIC TECHNOLOGY
    • MARKET RESTRAINTS
      • INEFFICIENCY IN IDENTIFICATION AND VALIDATION OF BIOMARKER
      • PRESENCE OF COMPLEX REGULATORY FRAMEWORK
      • LACK OF REIMBURSEMENT PROVISION IN INSURANCE FOR EPIGENOMIC
    • MARKET OPPORTUNITIES
      • INCREASING AWARENESS ABOUT EPIGENOMIC
      • ADVANCEMENT OF POTENTIAL IN EMERGING MARKETS
      • EXPANDING APPLICATIONS OF EPIGENETICS IN PERSONALIZED MEDICINE AND TARGETED THERAPY
      • USE OF EPIGENOMIC IN NON-ONCOLOGY APPLICATIONS
    • MARKET CHALLENGES
      • SCARCITY OF TRAINED PROFESSIONALS
      • HIGH COST OF INSTRUMENTS AND CONSUMABLES
  1. MARKET BY PRODUCT
    • REAGENTS
    • KITS
    • INSTRUMENTS
    • ENZYMES
    • SERVICES
  2. MARKET BY TECHNOLOGY
    • DNA METHYLATION
    • HISTONE METHYLATION & ACETYLATION
    • MICRORNA MODIFICATION
  3. MARKET BY APPLICATION
    • ONCOLOGY
      • DNA METHYLTRANSFERASE INHIBITORS
      • HISTONE DEACETYLASE INHIBITORS
    • NON-ONCOLOGY
  4. MARKET BY APPLICATION AREA
    • DIAGNOSIS
    • DRUG DISCOVERY
    • THERAPY OPTIMIZATION
    • PROGNOSIS
  5. MARKET BY SEGMENT
    • EPIGENETIC DIAGNOSIS
      • CANCER
      • NEURO
        • MENTAL RETARDATION
        • ALZHEIMER’S DISEASE
        • DEPRESSION
        • OTHER
      • CARDIOVASCULAR
        • VASCULAR DISEASE
        • HEART FAILURE
        • OTHERS
      • INFLAMMATORY & AUTOIMMUNE DISEASE
        • RHEUMATOID ARTHRITIS
        • DIABETES
        • LUPUS
        • MULTIPLE SCLEROSIS
        • INFLAMMATORY BOWEL DISEASES
      • R&D
        • DNA METHYLATION IN CANCER DETECTION
        • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
        • MECHANISMS OF EPIGENETIC GENE SILENCING
      • PERSONALIZED MEDICINE
        • CANCER TREATMENT
          • LUNG CANCER
          • SOLID CANCERS
          • GASTRIC CANCER
          • HEMATOLOGICAL CANCERS
          • OTHERS
        • NEUROLOGICAL DISORDERS
          • MENTAL RETARDATION
          • HUNTINGTON’S DISEASE
          • PARKINSON’S DISEASE
          • ALZHEIMER’S DISEASE
          • DEPRESSION
        • CVD
        • OTHERS
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • MYELODYSPLASTIC SYNDROMES
          • MULTIPLE SCLEROSIS
          • OBESITY
          • INFLAMMATORY BOWEL DISEASES
          • LUPUS
          • OTHER
        • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • UNITED KINGDOM
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • AFFYMETRIX
    • AGILENT TECHNOLOGIES
    • ASTELLAS PHARMACEUTICALS
    • BAYER AG
    • BIO VISION
    • CELGENE CORP.
    • EPIGENOMICS AG
    • EPIGENTEK
    • GLAXOSMITHKLINE
    • ILLUMINA INC.
    • JOHNSON & JOHNSON
    • LABORATORY CORP. OF AMERICA HOLDINGS
    • MERCK SHARP & DOHME
    • NATUREWISE BIOTECH & MEDICALS CORP.
    • NOVARTIS PHARMA AG
    • ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
    • TBG DIAGNOSTICS LIMITED
    • RUBICON GENOMICS
    • ROCHE HOLDING AG

LIST OF TABLES

TABLE 1 GLOBAL EPIGENOMIC MARKET, BY GEOGRAPHY, 2018-2026, (IN $ TEN THOUSAND)

TABLE 2 GLOBAL EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)

TABLE 3 GLOBAL REAGENTS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 4 GLOBAL KITS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 5 GLOBAL INSTRUMENTS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 6 GLOBAL ENZYMES MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 7 GLOBAL SERVICES MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 8 GLOBAL EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)

TABLE 9 GLOBAL DNA METHYLATION MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 10 GLOBAL HISTONE METHYLATION AND ACETYLATION MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 11 GLOBAL MICRO-RNA MODIFICATION MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 12 GLOBAL EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 13 GLOBAL EPIGENOMICS APPLICATION MARKET, BY ONCOLOGY, 2018-2026 (IN $ TEN THOUSAND)

TABLE 14 GLOBAL ONCOLOGY MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 15 GLOBAL DNA METHYLTRANSFERASE INHIBITORS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 16 GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 17 GLOBAL NON-ONCOLOGY MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 18 GLOBAL EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)

TABLE 19 GLOBAL DIAGNOSIS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 20 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 21 GLOBAL THERAPY OPTIMIZATION MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 22 GLOBAL PROGNOSIS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 23 GLOBAL EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)

TABLE 24 GLOBAL EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)

TABLE 25 GLOBAL EPIGENETIC DIAGNOSIS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 26 GLOBAL EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)

TABLE 27 GLOBAL EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)

TABLE 28 GLOBAL EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)

TABLE 29 GLOBAL EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)

TABLE 30 GLOBAL EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)

TABLE 31 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 32 GLOBAL PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

TABLE 33 GLOBAL PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)

TABLE 34 GLOBAL PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)

TABLE 35 GLOBAL EPIGENETIC THERAPIES MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 36 GLOBAL EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)

TABLE 37 GLOBAL BIOMARKERS MARKET, BY REGION, 2018-2026, (IN $ TEN THOUSAND)

TABLE 38 OPPORTUNITY MATRIX

TABLE 39 VENDOR LANDSCAPE

TABLE 40 GLOBAL EPIGENOMIC MARKET, BY GEOGRAPHY, 2018-2026, (IN $ TEN THOUSAND)

TABLE 41 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

TABLE 42 EUROPE EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

TABLE 43 ASIA PACIFIC EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

FIGURE LIST

FIGURE 1 GLOBAL EPIGENOMIC MARKET SHARE, BY SEGMENT 2017 & 2026 (%)

FIGURE 2 NORTH AMERICA EPIGENOMIC MARKET, 2018 – 2026 (IN $ BILLION)

FIGURE 3 ASIA PACIFIC REVENUE ESTIMATION ($ TEN THOUSAND)

FIGURE 4 REAGENTS ESTIMATED REVENUE ($TEN THOUSAND)

FIGURE 5 EPIGENETIC DIAGNOSIS ESTIMATED REVENUE ($ TEN THOUSAND

FIGURE 6 PERSONALIZED MEDICINES ESTIMATED REVENUE ($ TEN THOUSAND)

FIGURE 7 ONCOLOGY REVENUE ESTIMATION ($ TEN THOUSAND)

FIGURE 8 NON-ONCOLOGY REVENUE ESTIMATION ($ TEN THOUSAND)

FIGURE 9 GLOBAL EPIGENOMIC MARKET, BY REAGENTS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 10 GLOBAL EPIGENOMIC MARKET, BY KITS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 11 GLOBAL EPIGENOMIC MARKET, BY INSTRUMENTS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 12 GLOBAL EPIGENOMIC MARKET, BY ENZYMES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 13 GLOBAL EPIGENOMIC MARKET, BY SERVICES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 14 GLOBAL EPIGENOMIC MARKET, BY DNA METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 15 GLOBAL EPIGENOMIC MARKET, BY HISTONE METHYLATION AND ACETYLATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 16 GLOBAL EPIGENOMIC MARKET, BY MICRO-RNA MODIFICATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 17 GLOBAL EPIGENOMIC MARKET, BY ONCOLOGY, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 18 GLOBAL EPIGENOMIC MARKET, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 19 GLOBAL EPIGENOMIC MARKET, BY HISTONE DEACETYLASE INHIBITORS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 20 GLOBAL EPIGENOMIC MARKET, BY NON-ONCOLOGY, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 21 GLOBAL EPIGENOMIC MARKET, BY DIAGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 22 GLOBAL EPIGENOMIC MARKET, BY DRUG DISCOVERY, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 23 GLOBAL EPIGENOMIC MARKET, BY THERAPY OPTIMIZATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 24 GLOBAL EPIGENOMIC MARKET, BY PROGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 25 GLOBAL EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 26 GLOBAL EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS-CANCER, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 27 GLOBAL EPIGENOMIC MARKET, BY NEURO-MENTAL RETARDATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 28 GLOBAL EPIGENOMIC MARKET, BY NEURO- ALZHEIMER’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 29 GLOBAL EPIGENOMIC MARKET, BY NEURO- DEPRESSION, 2018-2 026, (IN $ TEN THOUSAND)

FIGURE 30 GLOBAL EPIGENOMIC MARKET, BY NEURO- OTHER, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 31 GLOBAL EPIGENOMIC MARKET, BY CARDIOVASCULAR-VASCULAR DISEASE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 32 GLOBAL EPIGENOMIC MARKET, BY CARDIOVASCULAR- HEART FAILURE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 33 GLOBAL EPIGENOMIC MARKET, BY CARDIOVASCULAR- OTHERS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 34 GLOBAL EPIGENOMIC MARKET, BY RHEUMATOID ARTHRITIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 35 GLOBAL EPIGENOMIC MARKET, BY DIABETES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 36 GLOBAL EPIGENOMIC MARKET, BY LUPUS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 37 GLOBAL EPIGENOMIC MARKET, BY MULTIPLE SCLEROSIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 38 GLOBAL EPIGENOMIC MARKET, BY INFLAMMATORY BOWEL DISEASES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 39 GLOBAL EPIGENOMIC MARKET, BY DNA METHYLATION IN CANCER DETECTION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 40 GLOBAL EPIGENOMIC MARKET, BY IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 41 GLOBAL EPIGENOMIC MARKET, BY MECHANISMS OF EPIGENETIC GENE SILENCING, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 42 GLOBAL EPIGENOMIC MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 43 GLOBAL EPIGENOMIC MARKET, BY LUNG CANCER, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 44 GLOBAL EPIGENOMIC MARKET, BY SOLID CANCERS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 45 GLOBAL EPIGENOMIC MARKET, BY GASTRIC CANCER, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 46 GLOBAL EPIGENOMIC MARKET, BY HEMATOLOGICAL CANCERS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 47 GLOBAL EPIGENOMIC MARKET, BY OTHERS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 48 GLOBAL EPIGENOMIC MARKET, BY MENTAL RETARDATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 49 GLOBAL EPIGENOMIC MARKET, BY HUNTINGTON’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 50 GLOBAL EPIGENOMIC MARKET, BY PARKINSON’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 51 GLOBAL EPIGENOMIC MARKET, BY ALZHEIMER’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 52 GLOBAL EPIGENOMIC MARKET, BY DEPRESSION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 53 GLOBAL EPIGENOMIC MARKET, BY CVD, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 54 GLOBAL EPIGENOMIC MARKET, BY RHEUMATOID ARTHRITIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 55 GLOBAL EPIGENOMIC MARKET, BY DIABETES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 56 GLOBAL EPIGENOMIC MARKET, BY MYELODYSPLASTIC SYNDROMES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 57 GLOBAL EPIGENOMIC MARKET, BY MULTIPLE SCLEROSIS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 58 GLOBAL EPIGENOMIC MARKET, BY OBESITY, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 59 GLOBAL EPIGENOMIC MARKET, BY INFLAMMATORY BOWEL DISEASES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 60 GLOBAL EPIGENOMIC MARKET, BY LUPUS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 61 GLOBAL EPIGENOMIC MARKET, BY OTHER, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 62 GLOBAL EPIGENOMIC MARKET, BY EPIGENETIC THERAPIES, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 63 GLOBAL EPIGENOMIC MARKET, BY BIOMARKERS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 64 GLOBAL EPIGENOMIC MARKET, BY DNA METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 65 GLOBAL EPIGENOMIC MARKET, BY HISTONIC MODIFICATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 66 GLOBAL EPIGENOMIC MARKET, BY HISTONE METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 67 GLOBAL EPIGENOMIC MARKET, BY HISTONE ACETYLATION, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 68 GLOBAL EPIGENOMIC MARKET, BY NONCODING RNAS, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 69 GLOBAL EPIGENOMIC MARKET, BY MIRNAS, 20 18-2026, (IN $ TEN THOUSAND)

FIGURE 70 GLOBAL EPIGENOMIC MARKET, BY CHROMATIN REMODELING, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 71 PORTER’S FIVE FORCE MODEL

FIGURE 72 GLOBAL EPIGENOMIC MARKET, REGIONAL OUTLOOK, 2018-2026, (IN $ TEN THOUSAND)

FIGURE 73 UNITED STATES EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 74 CANADA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 75 GERMANY EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 76 UNITED KINGDOM EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 77 FRANCE EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 78 ITALY EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 79 SPAIN EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 80 REST OF EUROPE EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 81 CHINA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 82 JAPAN EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 83 INDIA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 84 SOUTH KOREA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 85 REST OF ASIA PACIFIC EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 86 LATIN AMERICA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

FIGURE 87 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

  1. MARKET BY PRODUCT
    • REAGENTS
    • KITS
    • INSTRUMENTS
    • ENZYMES
    • SERVICES
  2. MARKET BY TECHNOLOGY
    • DNA METHYLATION
    • HISTONE METHYLATION & ACETYLATION
    • MICRORNA MODIFICATION
  3. MARKET BY APPLICATION
    • ONCOLOGY
      • DNA METHYLTRANSFERASE INHIBITORS
      • HISTONE DEACETYLASE INHIBITORS
    • NON-ONCOLOGY
  4. MARKET BY APPLICATION AREA
    • DIAGNOSIS
    • DRUG DISCOVERY
    • THERAPY OPTIMIZATION
    • PROGNOSIS
  5. MARKET BY SEGMENT
    • EPIGENETIC DIAGNOSIS
      • CANCER
      • NEURO
        • MENTAL RETARDATION
        • ALZHEIMER’S DISEASE
        • DEPRESSION
        • OTHER
      • CARDIOVASCULAR
        • VASCULAR DISEASE
        • HEART FAILURE
        • OTHERS
      • INFLAMMATORY & AUTOIMMUNE DISEASE
        • RHEUMATOID ARTHRITIS
        • DIABETES
        • LUPUS
        • MULTIPLE SCLEROSIS
        • INFLAMMATORY BOWEL DISEASES
      • R&D
        • DNA METHYLATION IN CANCER DETECTION
        • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
        • MECHANISMS OF EPIGENETIC GENE SILENCING
      • PERSONALIZED MEDICINE
        • CANCER TREATMENT
          • LUNG CANCER
          • SOLID CANCERS
          • GASTRIC CANCER
          • HEMATOLOGICAL CANCERS
          • OTHERS
        • NEUROLOGICAL DISORDERS
          • MENTAL RETARDATION
          • HUNTINGTON’S DISEASE
          • PARKINSON’S DISEASE
          • ALZHEIMER’S DISEASE
          • DEPRESSION
        • CVD
        • OTHERS
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • MYELODYSPLASTIC SYNDROMES
          • MULTIPLE SCLEROSIS
          • OBESITY
          • INFLAMMATORY BOWEL DISEASES
          • LUPUS
          • OTHER
        • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • UNITED KINGDOM
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now